CryoPort, Inc. (CYRX)
NASDAQIndustrialsIntegrated Freight & LogisticsSnapshot 2026-09-04
$15.81-0.32%
Close 2026-09-04 · 1-day change
NASDAQIndustrialsIntegrated Freight & LogisticsSnapshot 2026-09-04
QuarterlyIQ Insights · CYRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 12.9% |
| Our one-year growth estimate | diamond | 11.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 1.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 7 industry peers · Company calendar date is not available
CYRX — earnings in line
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Cryoport, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release issued by the Company is attached hereto as Exhibit 99.1. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…
Why it matters: This facility may help Cryoport serve more customers and increase capacity. This could affect future revenue.
Supportive ifThe new Global Supply Chain Center in Santa Ana, California opens as planned in Q4 2026.
Worry ifThe opening may be delayed or canceled. This would hurt plans for growth.
Why it matters: Positive adjusted EBITDA shows better profits and efficiency. It is a key step to making money.
Supportive ifAdjusted EBITDA is positive in Q3 2026. This shows that the company is making more money.
Worry ifAdjusted EBITDA is negative in Q3 2026. This shows that the company has profit problems.
Why it matters: Better gross margins mean improved cost management. They also show stronger pricing power in services.
Supportive ifGross margin for Life Sciences Services improves above 49.9% in Q3 2026.
Worry ifGross margin for Life Sciences Services declines below 49.9% in Q3 2026.
Why it matters: Improving gross profit shows better cost management and can lead to higher profits. This is key for growth.
Supportive ifGross profit increases to over $22M in the next quarter.
Worry ifGross profit remains below $21.9M in the next quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$174 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $431 loss on $10,000 · 4.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,150 loss on $10,000 · 31.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Management raised full-year revenue guidance to $192-$196 million. This shows confidence in growth.
Supportive ifManagement raises Q3 revenue guidance to over $49 million. This shows growth is continuing.
Worry ifManagement keeps Q3 revenue guidance at or below $49 million. This shows growth worries.
Why it matters: Better gross profit means better cost control. This helps overall profits.
Supportive ifGross profit increases year over year by more than 5%.
Worry ifGross profit declines or stays flat year over year.
Why it matters: Raising revenue guidance shows confidence in growth. It can boost investor trust.
Supportive ifManagement raised its revenue guidance for the year to over $50M.
Worry ifManagement keeps revenue guidance at or below $47.8M.
Why it matters: The launch of new centers is crucial for expanding service capabilities and supporting growth. Delays could hinder momentum.
Supportive ifBioServices operations launch in Paris and Santa Ana is on track for Q4 2026.
Worry ifDelays in launching the Global Supply Chain Centers beyond Q4 2026.
Why it matters: Supporting more clinical trials shows demand for services. It reflects company strength in the CGT market.
Supportive ifNumber of clinical trials supported increases beyond 779 in Q3 2026.
Worry ifThe number of clinical trials supported drops or stays below 779 in Q3 2026.
Why it matters: Better cash flow shows stronger financial health. It can support growth plans.
Supportive ifCash from operations exceeds $4M in the next quarter.
Worry ifCash from operations falls below $3M.
Why it matters: If the industrial sector's revenue growth speeds up, it could help CryoPort's performance.
Supportive ifSector revenue growth moves back toward 10% year over year.
Worry ifSector revenue growth continues to decline or stays below 5% year over year.
Why it matters: Better margins show improved cost control and pricing power. This can boost financial health.
Supportive ifGross margin improves from 46.6% in Q2 2026 to above 47% in Q3 2026.
Worry ifGross margin declines or remains below 46.6% in Q3 2026.
Why it matters: Strong revenue growth helps management raise full-year guidance. This shows continued demand.
Supportive ifQ2 revenue growth year-over-year meets or exceeds 16%.
Worry ifQ2 revenue growth year-over-year falls below 10%.
Why it matters: If growth exceeds 10%, it shows revenue is rising. This supports management's guidance.
Supportive ifQ3 revenue growth exceeds 10% year-over-year.
Worry ifQ3 revenue growth is below 5% year-over-year.
Why it matters: New therapy approvals show growth in cell and gene therapy. This helps Cryoport.
Supportive ifAt least 5 new therapy approvals occur by the end of 2026.
Worry ifFewer than 3 new therapy approvals occur by the end of 2026.
Why it matters: Opening the Paris center is an important growth step. It could improve service.
Supportive ifThe Global Supply Chain Center in Paris opens as planned in Q4 2026.
Worry ifThe opening of the Paris center is delayed beyond Q4 2026.